[시장보고서]세계의 섬유근육통 항우울제 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

세계의 섬유근육통 항우울제 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Fibromyalgia Antidepressants Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

상품코드 : 1495348

리서치사 : Persistence Market Research

발행일 : 2024년 06월

페이지 정보 : 영문 231 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 6,901,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,079,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 11,737,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

본 보고서는 세계 섬유근육통 항우울제 시장을 종합적으로 분석 및 예측한 Persistence Market Research 시장 조사 보고서입니다. 이 상세한 보고서는 주요 시장 역학, 성장 촉진요인, 도전, 신흥 동향에 대한 귀중한 통찰력을 제공합니다. 이 조사 보고서는 근육통증 항우울제 산업의 광범위한 개요를 제공하며 2024-2033년까지 시장 성장 궤도를 예측하는 독점 데이터와 통계를 제시합니다.

주요 인사이트

섬유근육통 항우울제 시장 규모(2024년) : 5억 8,123만 달러
예측 시장 매출(2033년) 11억 8,220만 달러
시장의 성장률(복합 연간 성장률(CAGR) 2024-2033년) : 8.2%

섬유근육통 항우울제 시장 : 조사 범위

섬유근육통 항우울제 시장은 만성 통증 질환인 섬유근통증의 유병률 증가와 증상 관리를 위한 치료 옵션으로서 항우울제의 채용 확대에 견인되어 큰 성장을 이룬다 있습니다. 이 시장은 건강 관리 제공업체, 환자 및 제약 회사에 서비스를 제공하고 섬유근통에 수반되는 통증, 피로, 수면장애를 완화시키는 효과가 입증된 항우울제를 제공합니다. 선택적 세로토닌 재 흡수 억제제(SSRI), 세로토닌 노르 에피네프린 재 흡수 억제제(SNRI), 삼환계 항우울제(TCA)와 같은 항우울제는 섬유 근육 통증 관리를위한 적응 외 처방 하는 것이 일반적이며, 이환자에게 완화를 가져오고, 생활의 질을 향상시키고 있습니다. 시장 성장의 원동력이 되고 있는 것은 질병에 대한 인식 증가, 환자 교육, 다제 병용 섬유근통증 치료 어프로치의 일환으로서 항우울제의 사용을 지지하는 임상 연구입니다.

시장 성장 촉진요인:

섬유 근육 통증 항우울제 시장은 몇 가지 주요 시장 성장 촉진요인의 혜택을 받고 있습니다. 섬유근통증의 유병률 상승과 이에 따른 건강 관리 시스템에 대한 부담은 시장 확대의 원동력입니다. 섬유근통증은 만성 통증과 피로에서인지 기능 장애 및 기분 장애에 이르기까지 다양한 증상을 나타내며 세계 수백만 명이 앓고 있으며 환자의 예후를 개선하는 효과 치료 옵션이 필요합니다. 또한, 섬유근통증 관리에 있어서의 항우울제의 적응외 사용은 진통 작용, 항불안 작용, 수면 촉진 작용을 나타내는 임상 근거에 지지되고 있어 의료 종사자나 환자의 사이에서 그 채용이 진행되어 있습니다. 또한, 제약 연구 및 의약품 개발의 진보로 섬유근통증의 증상 완화를 위한 내약성, 안전성 프로파일, 치료 효과가 개선된 신규 항우울제 제제가 도입되고 있습니다.

시장 성장 억제요인:

섬유근육통 항우울제 시장은 그 유망한 성장 전망에도 불구하고, 치료 효과, 안전 우려, 환자 어드히어런스에 관한 문제에 직면하고 있습니다. 항우울제는 모든 섬유근통증 환자에게 충분한 진통 효과나 증상의 개선을 초래하지는 않으며, 치료 중단이나 약물 전환으로 이어질 수 있습니다. 또한, 항우울제의 사용은 메스꺼움, 현기증, 체중 증가, 성기능 장애 등과 같은 잠재적인 부작용과 관련되어 환자의 수용 및 컴플라이언스를 제한할 수 있습니다. 게다가, 항우울제 치료에 대한 반응의 개인차, 유전적 요인 및 병존 질환은 치료의 복잡성의 원인이며, 맞춤 치료 접근이 필요할 수 있습니다. 이러한 장벽에 대처하기 위해서는 항우울제의 사용을 최적화하고 섬유근통증의 치료 성적을 개선하기 위한 임상 연구, 환자 교육, 의료 종사자 교육에 대한 투자가 필요합니다.

시장 기회:

Fibromyalgia 항우울제 시장은 치료 혁신, 환자 중심 치료, 개인화된 의료 접근법을 통해 큰 성장 기회를 제공합니다. 서방형 제형, 병용 요법, 표적 약물 전달 시스템과 같은 새로운 항우울제 제제의 개발은 개별 환자의 필요와 선호도에 맞게 맞춤형 치료 요법을 가능하게 합니다. 게다가 생활습관 개선, 물리치료, 심리사회적 지원 등 전인적인 섬유근통증 관리가 중시되어 여러 치료 접근법의 일부로 항우울제 치료를 통합한 통합 케어 모델 기회가 탄생했습니다. 또한 전략적 파트너십, 환자 옹호 단체와의 협력, 규제 당국과의 관계는 섬유근통증의 증상 완화를 위한 혁신적인 항우울제 치료제 개척, 시장 진입, 환자 접근을 촉진합니다.

이 보고서에서 다루는 주요 질문

섬유근육통 항우울제 시장의 세계 성장을 가속하는 요인은 무엇인가?
항우울제 연구와 의약품 개발의 진보는 섬유근통증 치료경쟁 구도를 어떻게 형성하는가?
Fibromyalgia 항우울제 부문 시장 진출 기업이 직면하는 주요 도전과 기회는?
항우울제 제조업체에게 가장 높은 성장 가능성을 제공하는 환자 집단과 지역은 어디입니까?
시장 경쟁력을 유지하기 위해 대기업은 어떤 전략을 취하고 있는가?

소개/ 주요 조사 결과
시장 규모(100만 달러)의 역사적 분석 : 약제별(2019년-2023년)
현재 및 장래 시장 규모(100만 달러)의 분석과 예측 : 약제별(2024년-2033년)
- 벤라팍신
- 듀록세틴 염산염
- 밀나시플란 염산염
- 기타
시장 매력 분석 : 약제별

제9장 세계 섬유근육통 항우울제 시장 분석 : 유통 채널별

소개/ 주요 조사 결과
시장 규모(100만 달러)의 역사적 분석 : 유통채널별(2019년-2023년)
현재 및 장래 시장 규모(100만 달러)의 분석과 예측 : 유통 채널별(2024년-2033년)
- 병원 약국
- 약국
- 소매 약국
- 온라인 약국
시장 매력 분석 : 유통 채널별

제10장 세계 섬유근육통 항우울제 시장 분석 : 지역별

소개/ 주요 조사 결과
시장 규모(100만 달러)의 역사적 분석 : 지역별별(2019년-2023년)
현재 및 장래 시장 규모(100만 달러)의 분석과 예측 :지역별(2024년-2033년)
- 북미
- 라틴아메리카
- 유럽
- 동아시아
- 남아시아
- 오세아니아
- 중동 및 아프리카
시장 매력 분석 : 지역별

제11장 북미의 섬유근육통 항우울제 시장 분석

제12장 라틴아메리카의 섬유근육통 항우울제 시장 분석

제13장 유럽 섬유근육통 항우울제 시장 분석

제14장 동아시아의 섬유근육통 항우울제 시장 분석

제15장 남아시아의 섬유근육통 항우울제 시장 분석

제16장 오세아니아의 섬유근육통 항우울제 시장 분석

제17장 중동 및 아프리카의 섬유근육통 항우울제 시장 분석

제18장 시장 구조 분석

기업 Tier별 시장 분석
주요 기업의 시장 점유율 분석
시장현재분석

제19장 경쟁 분석

경쟁 대시보드
경쟁 벤치마킹
경쟁의 상세
- Pfizer, Inc.
- Eli Lilly and Company
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
- Johnson &Johnson Services, Inc
- Sanofi
- GlaxoSmithKline plc.
- Bayer AG
- TONIX Pharmaceuticals Holdings Corp
- Virios Therapeutics, Inc.
- Aptinyx Inc.
- FSD Pharma

제20장 사용된 전제조건과 약어

제21장 조사 방법

BJH

영문 목차

영문목차

Persistence Market Research, a trusted market research firm, has conducted a comprehensive analysis of the global Fibromyalgia Antidepressants Market. This detailed report provides valuable insights into key market dynamics, growth drivers, challenges, and emerging trends. It offers an extensive overview of the fibromyalgia antidepressants industry, presenting exclusive data and statistics projecting the market's growth trajectory from 2024 to 2033.

Key Insights:

Fibromyalgia Antidepressants Market Size (2024): US$ 581.23 Mn
Projected Market Value (2033): US$ 1182.20 Mn
Global Market Growth Rate (CAGR 2024 to 2033):8.2%

Fibromyalgia Antidepressants Market - Report Scope:

The Fibromyalgia Antidepressants Market is witnessing significant growth, driven by the increasing prevalence of fibromyalgia, a chronic pain condition, and the growing adoption of antidepressants as a treatment option for symptom management. This market serves healthcare providers, patients, and pharmaceutical companies, offering antidepressant medications with proven efficacy in alleviating pain, fatigue, and sleep disturbances associated with fibromyalgia. Antidepressants, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs), are commonly prescribed off-label for fibromyalgia management, providing relief and improving quality of life for affected individuals. Market growth is fueled by increasing disease awareness, patient education, and clinical research supporting the use of antidepressants as part of multimodal fibromyalgia treatment approaches.

Market Growth Drivers:

The global Fibromyalgia Antidepressants Market benefits from several key growth drivers. The rising prevalence of fibromyalgia and the associated burden on healthcare systems drive market expansion. Fibromyalgia affects millions of individuals worldwide, with symptoms ranging from chronic pain and fatigue to cognitive dysfunction and mood disturbances, necessitating effective treatment options to improve patient outcomes. Moreover, the off-label use of antidepressants in fibromyalgia management is supported by clinical evidence demonstrating their analgesic, anxiolytic, and sleep-promoting effects, enhancing their adoption among healthcare providers and patients. Additionally, advancements in pharmaceutical research and drug development lead to the introduction of novel antidepressant formulations with improved tolerability, safety profiles, and treatment efficacy for fibromyalgia symptom relief.

Market Restraints:

Despite its promising growth prospects, the Fibromyalgia Antidepressants Market faces challenges related to treatment efficacy, safety concerns, and patient adherence. Antidepressants may not provide adequate pain relief or symptom improvement for all fibromyalgia patients, leading to treatment discontinuation and medication switching. Moreover, antidepressant use is associated with potential side effects, including nausea, dizziness, weight gain, and sexual dysfunction, which may limit patient acceptance and compliance. Furthermore, variations in individual response to antidepressant therapy, genetic factors, and comorbidities contribute to treatment complexity and may require personalized treatment approaches. Addressing these barriers requires investment in clinical research, patient education, and healthcare provider training to optimize antidepressant use and improve fibromyalgia management outcomes.

Market Opportunities:

The Fibromyalgia Antidepressants Market presents significant growth opportunities driven by therapeutic innovation, patient-centric care, and personalized medicine approaches. The development of novel antidepressant formulations, including extended-release formulations, combination therapies, and targeted drug delivery systems, enables customized treatment regimens tailored to individual patient needs and preferences. Moreover, the growing emphasis on holistic fibromyalgia management, including lifestyle modifications, physical therapy, and psychosocial support, creates opportunities for integrated care models incorporating antidepressant therapy as part of multimodal treatment approaches. Furthermore, strategic partnerships, collaborations with patient advocacy groups, and engagement with regulatory agencies facilitate drug development, market access, and patient access to innovative antidepressant therapies for fibromyalgia symptom relief.

Key Questions Answered in the Report:

What factors are driving the growth of the Fibromyalgia Antidepressants Market globally?
How are advancements in antidepressant research and drug development shaping the competitive landscape of fibromyalgia treatment?
What are the key challenges and opportunities facing market participants in the fibromyalgia antidepressants segment?
Which patient populations and geographic regions offer the highest growth potential for antidepressant manufacturers?
What strategies are leading companies employing to maintain their competitive edge in the market?

Competitive Intelligence and Business Strategy:

Leading players in the global Fibromyalgia Antidepressants Market, including [Insert Key Companies], focus on innovation, patient-centricity, and market expansion to gain a competitive edge. These companies invest in research and development to develop next-generation antidepressant therapies, explore new treatment modalities, and expand their product portfolios to address unmet patient needs and market gaps. Collaborations with academic institutions, clinical research organizations, and patient advocacy groups enable companies to conduct clinical trials, generate real-world evidence, and obtain regulatory approvals for novel antidepressant indications and formulations. Moreover, emphasis on patient education, support programs, and digital health solutions enhances medication adherence, treatment outcomes, and patient satisfaction in the competitive landscape of fibromyalgia management.

Key Companies Profiled:

Pfizer, Inc.
Eli Lilly and Company
AbbVie, Inc.
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc
Sanofi
GlaxoSmithKline plc.
Bayer AG
TONIX Pharmaceuticals Holdings Corp
Virios Therapeutics, Inc.
Aptinyx Inc.
FSD Pharma

Fibromyalgia Antidepressants Market Research Segmentation:

Drug:

Venlafaxine
Duloxetine HCl
Milnacipran HCl
Others

Distribution Channel:

Hospitals Pharmacies
Drug Stores
Retail Pharmacies
Online Pharmacies

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Product Adoption Analysis
4.2. Regulatory Landscape
4.3. Reimbursement Scenario
4.4. Drug Pipeline Assessment
4.5. Value Chain Analysis
4.6. PESTEL Analysis
4.7. Porter's Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Global Fibromyalgia Treatment Market Overview
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Rising Cases of Chronic Neurological Disorders
- 5.2.2. Growing Prevalence of Infectious Diseases
- 5.2.3. New Drug Approval Activities
- 5.2.4. Increasing R&D on Novel Disease Therapeutics
- 5.2.5. Large Drug Pipeline
- 5.2.6. Adoption of Off-Label Drugs
- 5.2.7. Availability of Reimbursement
- 5.2.8. Cost of Approved Drugs
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Drug
- 6.1.2. By Distribution Channel
- 6.1.3. By Country
6.2. 2024 Market Scenario

7. Global Fibromyalgia Antidepressants Market Demand (in Value or Size in US$ MN) Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Value (US$ MN) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ MN) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Fibromyalgia Antidepressants Market Analysis 2019-2023 and Forecast 2024-2033, By Drug

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ MN) Analysis By Drug, 2019-2023
8.3. Current and Future Market Size (US$ MN) Analysis and Forecast By Drug, 2024-2033
- 8.3.1. Venlafaxine
- 8.3.2. Duloxetine HCl
- 8.3.3. Milnacipran HCl
- 8.3.4. Others
8.4. Market Attractiveness Analysis By Drug

9. Global Fibromyalgia Antidepressants Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ MN) Analysis, By Distribution Channel, 2019-2023
9.3. Current and Future Market Size (US$ MN) Analysis and Forecast By Distribution Channel, 2024-2033
- 9.3.1. Hospitals Pharmacies
- 9.3.2. Drug Stores
- 9.3.3. Retail Pharmacies
- 9.3.4. Online Pharmacies
9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Fibromyalgia Antidepressants Market Analysis 2019-2023 and Forecast 2024-2033, By Region

10.1. Introduction
10.2. Historical Market Size (US$ MN) Analysis By Region, 2019-2023
10.3. Current and Future Market Value (US$ MN) Analysis and Forecast, By Region 2024-2033
- 10.3.1. North America
- 10.3.2. Latin America
- 10.3.3. Europe
- 10.3.4. East Asia
- 10.3.5. South Asia
- 10.3.6. Oceania
- 10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region

11. North America Fibromyalgia Antidepressants Market Analysis 2019-2023 and Forecast 2024-2033

11.1. Introduction
11.2. Historical Market Size (US$ MN) Trend Analysis By Market Taxonomy, 2019-2023
11.3. Current and Future Market Value (US$ MN) Analysis and Forecast, By Market Taxonomy, 2024-2033
- 11.3.1. By Country
  - 11.3.1.1. U.S.
  - 11.3.1.2. Canada
- 11.3.2. By Drug
- 11.3.3. By Distribution Channel
11.4. Market Attractiveness Analysis
- 11.4.1. By Country
- 11.4.2. By Drug
- 11.4.3. By Distribution Channel
11.5. Market Trends
11.6. Drivers and Restraints - Impact Analysis
11.7. Key Players - Intensity Mapping
11.8. Country Level Analysis & Forecast
- 11.8.1. U.S. Fibromyalgia Antidepressants Market Analysis
  - 11.8.1.1. Introduction
  - 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 11.8.1.2.1. By Drug
    - 11.8.1.2.2. By Distribution Channel
- 11.8.2. Canada Fibromyalgia Antidepressants Market Analysis
  - 11.8.2.1. Introduction
  - 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 11.8.2.2.1. By Drug
    - 11.8.2.2.2. By Distribution Channel

12. Latin America Fibromyalgia Antidepressants Market Analysis 2019-2023 and Forecast 2024-2033

12.1. Introduction
12.2. Historical Market Size (US$ MN) Trend Analysis By Market Taxonomy, 2019-2023
12.3. Current and Future Market Value (US$ MN) Analysis and Forecast, By Market Taxonomy, 2024-2033
- 12.3.1. By Country
  - 12.3.1.1. Mexico
  - 12.3.1.2. Brazil
  - 12.3.1.3. Argentina
  - 12.3.1.4. Rest of Latin America
- 12.3.2. By Drug
- 12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Drug
- 12.4.3. By Distribution Channel
12.5. Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Key Players - Intensity Mapping
12.8. Country Level Analysis & Forecast
- 12.8.1. Mexico Fibromyalgia Antidepressants Market Analysis
  - 12.8.1.1. Introduction
  - 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.1.2.1. By Drug
    - 12.8.1.2.2. By Distribution Channel
- 12.8.2. Brazil Fibromyalgia Antidepressants Market Analysis
  - 12.8.2.1. Introduction
  - 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.2.2.1. By Drug
    - 12.8.2.2.2. By Distribution Channel
- 12.8.3. Argentina Fibromyalgia Antidepressants Market Analysis
  - 12.8.3.1. Introduction
  - 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.3.2.1. By Drug
    - 12.8.3.2.2. By Distribution Channel

13. Europe Fibromyalgia Antidepressants Market Analysis 2019-2023 and Forecast 2024-2033

13.1. Introduction
13.2. Historical Market Size (US$ MN) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ MN) Analysis and Forecast, By Market Taxonomy, 2024-2033
- 13.3.1. By Country
  - 13.3.1.1. Germany
  - 13.3.1.2. Italy
  - 13.3.1.3. France
  - 13.3.1.4. U.K.
  - 13.3.1.5. Spain
  - 13.3.1.6. BENELUX
  - 13.3.1.7. Russia
  - 13.3.1.8. Rest of Europe
- 13.3.2. By Drug
- 13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Drug
- 13.4.3. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Key Players - Intensity Mapping
13.8. Country Level Analysis & Forecast
- 13.8.1. Germany Fibromyalgia Antidepressants Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Drug
    - 13.8.1.2.2. By Distribution Channel
- 13.8.2. Italy Fibromyalgia Antidepressants Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Drug
    - 13.8.2.2.2. By Distribution Channel
- 13.8.3. France Fibromyalgia Antidepressants Market Analysis
  - 13.8.3.1. Introduction
  - 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.3.2.1. By Drug
    - 13.8.3.2.2. By Distribution Channel
- 13.8.4. U.K. Fibromyalgia Antidepressants Market Analysis
  - 13.8.4.1. Introduction
  - 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.4.2.1. By Drug
    - 13.8.4.2.2. By Distribution Channel
- 13.8.5. Spain Fibromyalgia Antidepressants Market Analysis
  - 13.8.5.1. Introduction
  - 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.5.2.1. By Drug
    - 13.8.5.2.2. By Distribution Channel
- 13.8.6. BENELUX Fibromyalgia Antidepressants Market Analysis
  - 13.8.6.1. Introduction
  - 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.6.2.1. By Drug
    - 13.8.6.2.2. By Distribution Channel
- 13.8.7. Russia Fibromyalgia Antidepressants Market Analysis
  - 13.8.7.1. Introduction
  - 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.7.2.1. By Drug
    - 13.8.7.2.2. By Distribution Channel

14. East Asia Fibromyalgia Antidepressants Market Analysis 2019-2023 and Forecast 2024-2033

14.1. Introduction
14.2. Historical Market Size (US$ MN) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ MN) Analysis and Forecast, By Market Taxonomy, 2024-2033
- 14.3.1. By Country
  - 14.3.1.1. China
  - 14.3.1.2. Japan
  - 14.3.1.3. South Korea
- 14.3.2. By Drug
- 14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Drug
- 14.4.3. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Players - Intensity Mapping
14.8. Country Level Analysis & Forecast
- 14.8.1. China Fibromyalgia Antidepressants Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Drug
    - 14.8.1.2.2. By Distribution Channel
- 14.8.2. Japan Fibromyalgia Antidepressants Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Drug
    - 14.8.2.2.2. By Distribution Channel
- 14.8.3. South Korea Fibromyalgia Antidepressants Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Drug
    - 14.8.3.2.2. By Distribution Channel

15. South Asia Fibromyalgia Antidepressants Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Historical Market Size (US$ MN) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ MN) Analysis and Forecast, By Market Taxonomy, 2024-2033
- 15.3.1. By Country
  - 15.3.1.1. India
  - 15.3.1.2. Indonesia
  - 15.3.1.3. Malaysia
  - 15.3.1.4. Thailand
  - 15.3.1.5. Rest of South Asia
- 15.3.2. By Drug
- 15.3.3. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug
- 15.4.3. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Players - Intensity Mapping
15.8. Country Level Analysis & Forecast
- 15.8.1. India Fibromyalgia Antidepressants Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Drug
    - 15.8.1.2.2. By Distribution Channel
- 15.8.2. Indonesia Fibromyalgia Antidepressants Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Drug
    - 15.8.2.2.2. By Distribution Channel
- 15.8.3. Malaysia Fibromyalgia Antidepressants Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Drug
    - 15.8.3.2.2. By Distribution Channel
- 15.8.4. Thailand Fibromyalgia Antidepressants Market Analysis
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.4.2.1. By Drug
    - 15.8.4.2.2. By Distribution Channel

16. Oceania Fibromyalgia Antidepressants Market 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Historical Market Size (US$ MN) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ MN) Analysis and Forecast, By Market Taxonomy, 2024-2033
- 16.3.1. By Country
  - 16.3.1.1. Australia
  - 16.3.1.2. New Zealand
- 16.3.2. By Drug
- 16.3.3. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Drug
- 16.4.3. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Players - Intensity Mapping
16.8. Country Level Analysis & Forecast
- 16.8.1. Australia Fibromyalgia Antidepressants Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Drug
    - 16.8.1.2.2. By Distribution Channel
- 16.8.2. New Zealand Fibromyalgia Antidepressants Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Drug
    - 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Fibromyalgia Antidepressants Market Analysis 2019-2023 and Forecast 2024-2033

17.1. Introduction
17.2. Historical Market Size (US$ MN) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ MN) Analysis and Forecast, By Market Taxonomy, 2024-2033
- 17.3.1. By Country
  - 17.3.1.1. GCC Countries
  - 17.3.1.2. Turkey
  - 17.3.1.3. North Africa
  - 17.3.1.4. South Africa
  - 17.3.1.5. Rest of Middle East and Africa
- 17.3.2. By Drug
- 17.3.3. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug
- 17.4.3. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Players - Intensity Mapping
17.8. Country Level Analysis & Forecast
- 17.8.1. GCC Countries Fibromyalgia Antidepressants Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Drug
    - 17.8.1.2.2. By Distribution Channel
- 17.8.2. Turkey Fibromyalgia Antidepressants Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Drug
    - 17.8.2.2.2. By Distribution Channel
- 17.8.3. South Africa Fibromyalgia Antidepressants Market Analysis
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.3.2.1. By Drug
    - 17.8.3.2.2. By Distribution Channel
- 17.8.4. North Africa Fibromyalgia Antidepressants Market Analysis
  - 17.8.4.1. Introduction
  - 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.4.2.1. By Drug
    - 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis

19. Competition Analysis

19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
- 19.3.1. Pfizer, Inc.
  - 19.3.1.1. Overview
  - 19.3.1.2. Product Portfolio
  - 19.3.1.3. Sales Footprint
  - 19.3.1.4. Key Financials
  - 19.3.1.5. SWOT Analysis
  - 19.3.1.6. Strategy Overview
    - 19.3.1.6.1. Marketing Strategy
    - 19.3.1.6.2. Product Strategy
    - 19.3.1.6.3. Channel Strategy
- 19.3.2. Eli Lilly and Company
  - 19.3.2.1. Overview
  - 19.3.2.2. Product Portfolio
  - 19.3.2.3. Sales Footprint
  - 19.3.2.4. Key Financials
  - 19.3.2.5. SWOT Analysis
  - 19.3.2.6. Strategy Overview
    - 19.3.2.6.1. Marketing Strategy
    - 19.3.2.6.2. Product Strategy
    - 19.3.2.6.3. Channel Strategy
- 19.3.3. AbbVie, Inc.
  - 19.3.3.1. Overview
  - 19.3.3.2. Product Portfolio
  - 19.3.3.3. Sales Footprint
  - 19.3.3.4. Key Financials
  - 19.3.3.5. SWOT Analysis
  - 19.3.3.6. Strategy Overview
    - 19.3.3.6.1. Marketing Strategy
    - 19.3.3.6.2. Product Strategy
    - 19.3.3.6.3. Channel Strategy
- 19.3.4. Teva Pharmaceutical Industries Ltd.
  - 19.3.4.1. Overview
  - 19.3.4.2. Product Portfolio
  - 19.3.4.3. Sales Footprint
  - 19.3.4.4. Key Financials
  - 19.3.4.5. SWOT Analysis
  - 19.3.4.6. Strategy Overview
    - 19.3.4.6.1. Marketing Strategy
    - 19.3.4.6.2. Product Strategy
    - 19.3.4.6.3. Channel Strategy
- 19.3.5. Johnson & Johnson Services, Inc
  - 19.3.5.1. Overview
  - 19.3.5.2. Product Portfolio
  - 19.3.5.3. Sales Footprint
  - 19.3.5.4. Key Financials
  - 19.3.5.5. SWOT Analysis
  - 19.3.5.6. Strategy Overview
    - 19.3.5.6.1. Marketing Strategy
    - 19.3.5.6.2. Product Strategy
    - 19.3.5.6.3. Channel Strategy
- 19.3.6. Sanofi
  - 19.3.6.1. Overview
  - 19.3.6.2. Product Portfolio
  - 19.3.6.3. Sales Footprint
  - 19.3.6.4. Key Financials
  - 19.3.6.5. SWOT Analysis
  - 19.3.6.6. Strategy Overview
    - 19.3.6.6.1. Marketing Strategy
    - 19.3.6.6.2. Product Strategy
    - 19.3.6.6.3. Channel Strategy
- 19.3.7. GlaxoSmithKline plc.
  - 19.3.7.1. Overview
  - 19.3.7.2. Product Portfolio
  - 19.3.7.3. Sales Footprint
  - 19.3.7.4. Key Financials
  - 19.3.7.5. SWOT Analysis
  - 19.3.7.6. Strategy Overview
    - 19.3.7.6.1. Marketing Strategy
    - 19.3.7.6.2. Product Strategy
    - 19.3.7.6.3. Channel Strategy
- 19.3.8. Bayer AG
  - 19.3.8.1. Overview
  - 19.3.8.2. Product Portfolio
  - 19.3.8.3. Sales Footprint
  - 19.3.8.4. Key Financials
  - 19.3.8.5. SWOT Analysis
  - 19.3.8.6. Strategy Overview
    - 19.3.8.6.1. Marketing Strategy
    - 19.3.8.6.2. Product Strategy
    - 19.3.8.6.3. Channel Strategy
- 19.3.9. TONIX Pharmaceuticals Holdings Corp
  - 19.3.9.1. Overview
  - 19.3.9.2. Product Portfolio
  - 19.3.9.3. Sales Footprint
  - 19.3.9.4. Key Financials
  - 19.3.9.5. SWOT Analysis
  - 19.3.9.6. Strategy Overview
    - 19.3.9.6.1. Marketing Strategy
    - 19.3.9.6.2. Product Strategy
    - 19.3.9.6.3. Channel Strategy
- 19.3.10. Virios Therapeutics, Inc.
  - 19.3.10.1. Overview
  - 19.3.10.2. Product Portfolio
  - 19.3.10.3. Sales Footprint
  - 19.3.10.4. Key Financials
  - 19.3.10.5. SWOT Analysis
  - 19.3.10.6. Strategy Overview
    - 19.3.10.6.1. Marketing Strategy
    - 19.3.10.6.2. Product Strategy
    - 19.3.10.6.3. Channel Strategy
- 19.3.11. Aptinyx Inc.
  - 19.3.11.1. Overview
  - 19.3.11.2. Product Portfolio
  - 19.3.11.3. Sales Footprint
  - 19.3.11.4. Key Financials
  - 19.3.11.5. SWOT Analysis
  - 19.3.11.6. Strategy Overview
    - 19.3.11.6.1. Marketing Strategy
    - 19.3.11.6.2. Product Strategy
    - 19.3.11.6.3. Channel Strategy
- 19.3.12. FSD Pharma
  - 19.3.12.1. Overview
  - 19.3.12.2. Product Portfolio
  - 19.3.12.3. Sales Footprint
  - 19.3.12.4. Key Financials
  - 19.3.12.5. SWOT Analysis
  - 19.3.12.6. Strategy Overview
    - 19.3.12.6.1. Marketing Strategy
    - 19.3.12.6.2. Product Strategy
    - 19.3.12.6.3. Channel Strategy